Five New Medicine Recalls in the United States and Russia — 10 August 2026

On 10 August 2026, regulators in the United States and Russia published information on five medicine recalls with a documented patient-safety connection.

United States: three FDA recalls

Morphine sulfate: possible substitution with hydromorphone

Fresenius Kabi is recalling lot 6402820 of Morphine Sulfate Injection USP, Simplist 2 mg/1 mL. A MicroVault labelled as morphine may contain a Dilaudid (hydromorphone) syringe. The mix-up may cause life-threatening respiratory depression and death.

FDA recall notice

Compounded glutathione: elevated bacterial endotoxins

Victory Medical Center Pharmacy is recalling lots 1980571, 1981940 and 1984345 of Compounded Glutathione 200 mg/mL. Elevated bacterial endotoxin levels may cause fever, hypotension, inflammatory reactions, anaphylactic shock and death. Adverse events have been reported.

FDA recall notice

OPTIRAY: particulate matter

Liebel-Flarsheim is recalling lot 25ZF3670 of OPTIRAY Imaging Bulk Package 350, 500 mL. Plastic, stainless-steel and glass particles may cause local irritation or swelling and potentially life-threatening vascular blockage and blood clots.

FDA recall notice

Russia: two Roszdravnadzor recalls

AVEKSIMA Activated Charcoal

Letter No. 02I-910/26 stops circulation of lot 150824, 250 mg tablets, because the product failed the “uniformity of mass” specification. The official letter requires measures to eliminate a threat of harm to citizens’ life and health.

Roszdravnadzor record | Official letter (PDF)

Magnesium sulfate

Letter No. 02I-911/26 recalls lot 230425 of magnesium sulfate 250 mg/mL solution for intravenous administration, 10 mL ampoules, due to a labelling non-compliance. The official document also connects the required measures with eliminating a threat to life and health.

Roszdravnadzor record | Official letter (PDF)

Actions for marketing authorisation holders and supply-chain participants

• promptly identify the affected lots in the supply chain;
• implement applicable regulatory requirements and recall procedures;
• assess whether additional communication to healthcare professionals and patients is required;
• ensure that adverse reactions and medication errors are recorded and followed up.

This update is based on official FDA and Roszdravnadzor notices available as of 10 August 2026.